IBM Watson Health cuts back Drug Discovery ‘artificial intelligence’ after lackluster sales

And seemingly uses machine learning to explain why it’s kinda not but kinda is

IBM Watson Health is tapering off its Drug Discovery program, which uses “AI” software to help companies develop new pharmaceuticals, blaming poor sales.…

Source link

Related posts

eCLINICALWORKS Unveils Health Information Search Engine to Create Longitudinal View of Patient Record


Why your board needs an AI council


Building an interactive and scalable ML research environment using AWS ParallelCluster


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy